Enanta Pharmaceuticals Inc
ENTA7.640USD
-0.200-2.55%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
163.33MMarket Cap
LossP/E TTM
More Details of Enanta Pharmaceuticals Inc Company
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Company Info
Ticker SymbolENTA
Company nameEnanta Pharmaceuticals Inc
IPO dateMar 21, 2013
CEODr. Jay R. Luly, Ph.D.
Number of employees131
Security typeOrdinary Share
Fiscal year-endMar 21
Address4 Kingsbury Avenue
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone16176070800
Websitehttps://www.enanta.com/
Ticker SymbolENTA
IPO dateMar 21, 2013
CEODr. Jay R. Luly, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
Mr. Scott T. Rottinghaus, M.D.
Mr. Scott T. Rottinghaus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
14.93M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.89%
The Vanguard Group, Inc.
9.25%
BlackRock Institutional Trust Company, N.A.
7.38%
Millennium Management LLC
6.82%
Other
56.73%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.89%
The Vanguard Group, Inc.
9.25%
BlackRock Institutional Trust Company, N.A.
7.38%
Millennium Management LLC
6.82%
Other
56.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.40%
Investment Advisor/Hedge Fund
25.35%
Hedge Fund
24.72%
Individual Investor
6.76%
Research Firm
1.45%
Bank and Trust
0.32%
Family Office
0.19%
Pension Fund
0.13%
Insurance Company
0.04%
Other
6.66%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
315
20.02M
93.65%
-6.96M
2025Q1
342
20.11M
94.09%
-7.55M
2024Q4
348
21.38M
100.27%
-5.34M
2024Q3
354
22.65M
106.92%
-6.74M
2024Q2
352
23.60M
111.43%
-6.27M
2024Q1
361
24.29M
114.84%
-4.07M
2023Q4
373
21.96M
104.28%
-4.11M
2023Q3
375
22.04M
104.75%
-4.91M
2023Q2
376
21.98M
104.47%
-3.80M
2023Q1
380
21.64M
103.62%
-3.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
2.12M
9.93%
+14.00K
+0.66%
Mar 31, 2025
Krensavage Asset Management, LLC
2.12M
9.9%
-804.00
-0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.01M
9.39%
+23.27K
+1.17%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
8.05%
+3.27K
+0.19%
Mar 31, 2025
Millennium Management LLC
1.35M
6.3%
-35.34K
-2.56%
Mar 31, 2025
Acadian Asset Management LLC
867.04K
4.06%
+17.61K
+2.07%
Mar 31, 2025
Marshall Wace LLP
850.89K
3.98%
-79.20K
-8.52%
Mar 31, 2025
Luly (Jay R)
826.73K
3.87%
+62.57K
+8.19%
Feb 12, 2025
Stonepine Capital Management, LLC
590.74K
2.76%
+258.84K
+77.99%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
